Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
The Challenges of Signal Detection in Spontaneous Reporting
Posted on September 13th, 2017 by Sherry Winter in Pharmacovigilance
Pharmacovigilance is essential to pharmaceutical businesses. It facilitates the correct use of a drug, safeguarding the drug as a meaningful treatment option when the benefits it offers outweigh known risks, or measures can be taken to mitigate those risks.
Improving patient safety is a core objective of pharmacovigilance, but so is effective patient care. More than just monitoring for evidence that a drug triggers an adverse reaction, pharmacovigilance is a systematic, detailed and iterative examination of the risks that a drug poses to a patient population versus the benefits that it affords. It is about drug stewardship, with workflows designed to gather data and evaluate new knowledge to define when and how a drug should be used.
Dr. Laszlo Urban is Global Head of Preclinical Secondary Pharmacology at the Novartis Institutes for Biomedical Research. For over a decade, he has explored and successfully implemented systems to inform the development of new drugs with insights from the clinic about adverse events. As he sees it, “pharmacovigilance is a sentinel. It serves to draw drug developers’ attention to any aspect of a drug or group of drugs that can impact not only the way a drug is perceived, used and managed but also the way a company goes about developing new therapies.”
Unfortunately, the view of the “sentinel” is not always clear. Working with spontaneous adverse event reporting systems — that is, information that is voluntarily submitted to authorities or MAHs — poses challenges. Overcoming these requires not only gathering relevant data from multiple sources but also leveraging these to guide the process by which the connection between an adverse event and a drug is verified.
Read the white paper to learn more: Signal Detection in Spontaneous Reporting Databases — Sentinels in a Cluttered Landscape.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Solution Marketing Manager
- Webinar: Using machine learning to identify adverse events from scientific literature
- Why literature is a valuable source for signal detection: From the EU point of view
- Elsevier uses machine learning to benefit pharmacovigilance
- How Big Data Transforms Reactive Drug Safety to Proactive Pharmacovigilance
- Are Drug-Drug Interactions Today’s Biggest Health Threat?